Apogee Therapeutics (APGE) AI Stock Analysis

• Market Cap: $2.20B
• Dividend Yield: N/A
• Average Volume (3M): 765.52K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.59
• Revenue Growth: N/A
• EPS Growth: -94.92%
• Country: US
• Employees: 196
• Sector: Healthcare
• Sector Strength: 65
• Industry: Biotechnology
• EPS (TTM): -3.23
• Shares Outstanding: 46,016,540
• 10 Day Avg. Volume: 736,290
• 30 Day Avg. Volume: 765,518
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -8.80
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $93.63
• Price Target Upside: 152.71% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9

Apogee Therapeutics' stock score reflects the significant challenges it faces as an early-stage biotechnology company with no revenue and high operational expenses, offset by a robust cash position and positive corporate developments. The bearish technical trends and speculative valuation further weigh on the score. However, promising clinical trial results provide potential for future growth, making it a high-risk, high-reward investment.

Positive Factors

Competitive Advantage

The developments favor APG990, which binds an OX40L epitope, suggesting a competitive advantage for Apogee Therapeutics.

Financial Stability

APGE has $731.1 million in cash, cash equivalents, and marketable securities, expected to fund operations into the first quarter of 2028, providing financial stability.

Negative Factors

Conflict of Interest

Investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report.

Safety Concerns

Safety remains a negative differentiator for rocatinlimab, with new data disclosing pyrexia and chills rates consistent with prior rates.

Apogee Therapeutics Business Overview & Revenue Model

Company Description

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.

How the Company Makes Money

Apogee Therapeutics makes money primarily through the development and commercialization of its proprietary drug candidates. The company generates revenue through partnerships and collaborations with other pharmaceutical companies, licensing agreements, and potential milestone payments related to the successful development and commercialization of its therapies. Additionally, Apogee may earn revenue from selling its developed therapeutics once they receive regulatory approval and are brought to market.

Apogee Therapeutics Financial Statement Overview

Summary

Apogee Therapeutics exhibits financial characteristics typical of an early-stage biotechnology firm. The company has zero revenue and increasing operational expenses, resulting in profitability challenges. It relies heavily on equity financing, maintaining a strong cash position, but faces risks from high cash burn and negative free cash flow.

Income Statement

Apogee Therapeutics has reported zero revenue over the past three years, which is typical for early-stage biotechnology firms focusing on research and development. The company’s EBIT and EBITDA have significantly worsened, reflecting increased operational expenses without revenue offset. The absence of revenue growth and negative net income margins highlight substantial profitability challenges.

Balance Sheet

The balance sheet shows a strong equity position with a substantial increase in stockholders’ equity, driven by financing activities likely tied to capital raises. The debt-to-equity ratio remains low, indicating minimal leverage. However, total assets are primarily composed of cash and equivalents, which could indicate a lack of diversification in asset allocation.

Cash Flow

The company’s cash flow statement shows significant reliance on financing activities to fund operations, typical for biotech companies in the development phase. Operating cash flow is negative, consistent with its stage, but free cash flow has deteriorated, indicating increasing cash burn rates. This trend could pose liquidity risks if external funding becomes challenging.

Breakdown
Dec 2024	Dec 2023	Dec 2022
Income Statement		Total Revenue
0.00	0.00	0.00
	Gross Profit
0.00	0.00	0.00
	EBIT
-216.87M	-93.00M	-30.73M
	EBITDA
-216.87M	-83.98M	0.00
	Net Income Common Stockholders
0.00	-83.98M	-39.78M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
520.65M	395.46M	151.89M
	Total Assets
753.95M	401.40M	152.06M
	Total Debt
11.83M	2.03M	0.00
	Net Debt
-129.96M	-116.28M	-151.89M
	Total Liabilities
37.16M	21.49M	9.98M
	Stockholders Equity
716.79M	379.91M	-39.78M
Cash Flow		Free Cash Flow
-172.33M	-74.93M	-16.43M
	Operating Cash Flow
-171.17M	-74.76M	-16.43M
	Investing Cash Flow
-300.46M	-273.91M	0.00
	Financing Cash Flow
495.11M	315.39M	183.62K

Apogee Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 37.05
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APGE, the sentiment is Positive. The current price of 37.05 is above the 20-day moving average (MA) of 34.13, above the 50-day MA of 35.43, and below the 200-day MA of 45.12, indicating a neutral trend. The MACD of -0.26 indicates Negative momentum. The RSI at 55.22 is Neutral, neither overbought nor oversold. The STOCH value of 78.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for APGE.

Apogee Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LGND	66 Neutral	$2.09B	48.01	-0.53%	―	27.28%	-101.63%
TARS	54 Neutral	$2.08B	―	-54.83%	―	948.62%	33.12%
Sector *	51 Neutral	$5.31B	3.33	-39.82%	2.92%	17.95%	1.84%
APGE	45 Neutral	$2.20B	―	-33.22%	―	―	-94.92%
BLTE	41 Neutral	$1.85B	―	-30.60%	―	―	―
BHVN	35 Underperform	$2.39B	―	-198.83%	―	―	-65.63%

Apogee Therapeutics Corporate Events

Apogee Therapeutics Reports Positive Phase 1 Results

On March 3, 2025, Apogee Therapeutics announced positive interim Phase 1 results from its first-in-human trial of APG990, which exceeded trial objectives and demonstrated potential for extended dosing intervals. The company also reported significant progress in its pipeline, including the accelerated execution of the Phase 2 APEX clinical trial for APG777 and plans for further trials in asthma and eosinophilic esophagitis. Apogee’s strong financial position, with $731.1 million in cash and marketable securities, supports its operations into 2028, despite increased R&D and G&A expenses in 2024.

Apogee Therapeutics Advances APG777 in Key Phase 2 Trial

On February 3, 2025, Apogee Therapeutics announced the dosing of the first patient in the Part B portion of their Phase 2 APEX clinical trial for APG777, targeting patients with moderate-to-severe atopic dermatitis. The trial combines Phase 2a and 2b protocols, with Part A seeing an exceeded enrollment of 123 patients, and Part B involving approximately 280 patients. This advancement underscores APG777’s potential in providing effective treatment options with reduced injection burdens and improved disease control, positioning Apogee as a competitive player in the I&I markets.